H. Lundbeck, Lundbeck and Teva announce phase III trials did not demonstrate etilevodopa superiority over standard levodopa

H. Lundbeck A/S and Teva Pharmaceutical Industries Limited announced today the results of two phase III clinical studies with an immediate release formulation of etilevodopa, a soluble prodrug of levodopa, in advanced Parkinson’s Disease patients. Etilevodopa was found to be well tolerated and as effective as levodopa. On the primary endpoint, shortened the time to clinical effect, etilevodopa did not demonstrate statistically significant superiority over standard levodopa.